New research presented at Neuroscience 2026 indicates that biological sex and genetic makeup play critical roles in how neurological disorders develop and respond to medical interventions. The findings, shared at the annual meeting of the Society for Neuroscience, suggest that personalized treatment strategies are necessary for complex brain conditions.
Two specific conditions are receiving focused attention in these studies: Alzheimer’s disease and fibromyalgia. According to the World Health Organization, Alzheimer’s disease affects between 35 million and 40 million people globally. Fibromyalgia, a chronic illness characterized by persistent pain and fatigue, impacts approximately 2 to 4 percent of the global population. Understanding the biological differences between sexes could lead to more effective therapies for these difficult-to-treat disorders.
Menopause and Genetic Risk in Alzheimer’s
Two studies highlighted the intersection of menopause and inherited genetic factors in Alzheimer’s disease vulnerability. One investigation examined how individuals carrying genetic risk factors for the disease responded to menopause hormone therapy compared to those without such risks.
The data showed that treatment responses varied based on the specific combination of hormones used. This suggests that both a patient’s genetic background and the formulation of hormone therapy must be considered when evaluating treatment options for women at risk. Mateja Perovi from the University of Toronto led this investigation.

A separate study by Stephanie M. Perez at the University of Texas Health Science Center at San Antonio used rodent models to observe brain changes during menopause. The researchers found that brain circuits responsible for memory became particularly vulnerable in rodents carrying genetic risk factors for Alzheimer’s. This provides evidence that menopause represents a period of increased susceptibility for women who are genetically predisposed to the disease.
Sex Differences in Chronic Pain and Inflammation
Other research presented at the conference explored how biological sex influences pain sensitivity and immune activity. In a mouse model of fibromyalgia, female subjects continued to show heightened sensitivity to touch and stronger immune system activation compared to males. Yasmin Sahlloul from the University of Cincinnati noted that these findings suggest the biological processes contributing to chronic pain differ between sexes.
Another study investigated the relationship between prolonged intestinal inflammation and brain function. Nurcan Kilic from the University of North Dakota used a mouse model to find that chronic gut inflammation affected brain function and Alzheimer’s-related disease changes differently in males and females. These results add to the growing body of evidence that biological sex influences the connection between inflammation and neurological disease.

Liisa Galea, PhD, the Treliving Family Chair in Women’s Mental Health at the Centre for Addiction and Mental Health, moderated the press conference discussing these findings. She emphasized the importance of focusing on female-specific biology and sex differences in understanding Alzheimer’s disease symptoms and risk factors.
“The research presented at Neuroscience 2026 helps us pinpoint the specific differences that may help us develop more targeted treatment using precision approaches, even for some of our most complex brain disorders,” Galea said.
Together, these four studies underscore the necessity of examining sex and genetic differences in neurological research. By identifying the biological factors that drive disease progression and treatment responses, researchers aim to create more precise therapies for Alzheimer’s disease, fibromyalgia, and other challenging brain disorders.
Source: ScienceDaily

